Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. - Wikidata - wikimedia - TriplyDB

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models.

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models.

http://www.wikidata.org/entity/Q40577628

about

TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway Transcriptional regulation of chemokine expression in ovarian cancer Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer.Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer WNT5A-ROR2 is induced by inflammatory mediators and is involved in the migration of human ovarian cancer cell line SKOV-3 Pathogenesis of ovarian cancer: clues from selected overexpressed genes.Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells.Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling.miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy Calcitonin gene-related peptide inhibits chemokine production by human dermal microvascular endothelial cells.Moringa Oleifera aqueous leaf extract down-regulates nuclear factor-kappaB and increases cytotoxic effect of chemotherapy in pancreatic cancer cells.Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.Glycogen synthase kinase 3β inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occurs via NF-kappaB and mitochondrial cytochrome c cascade.NF-kappa B--a target in the inflammation of bone destruction.Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor κB kinase.Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance.IKK inhibition increases bortezomib effectiveness in ovarian cancer.Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells.Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway.NF-kappa B as a target for cancer therapy.Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor Resistance to chemotherapy in cancer: a complex and integrated cellular response.Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway.Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment Triptolide avoids cisplatin resistance and induces apoptosis via the reactive oxygen species/nuclear factor-κB pathway in SKOV3(PT) platinum-resistant human ovarian cancer cells.mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.rpL3 promotes the apoptosis of p53 mutated lung cancer cells by down-regulating CBS and NFκB upon 5-FU treatment

P2860

Q24336598-CCC04A90-7A1C-4317-9F51-C5CB916B8CC3 Q26825361-2D30CDC0-EC49-4E49-80A9-81CD2EDD7779 Q26858839-95A34D84-E397-49DC-A91A-15D4A0D68DBF Q28471740-EAC10FAD-FF03-448D-9F20-39CC1D0DB6AD Q28474516-4FDCA92E-5DCA-4490-9619-83DFF70D56F4 Q28535061-76A30DA9-AF25-492A-AAF4-BCC9E0C8C912 Q30444700-213A51CD-EF09-49AF-98A0-C341A4306624 Q33387721-E4EBC3C9-FCF3-4757-8523-47071115904A Q33634911-B4D30A4B-2504-4794-993C-FC8E5268F8E6 Q33651139-F8230362-9E98-4B3C-A77B-4B5E692C850F Q33713850-3D555569-BBF6-4DA0-8441-3E942D9AA044 Q33788519-223D42EF-8C52-40EC-A8C5-D75551939244 Q34139923-127749CB-D184-4887-B818-D0EF1F2B4285 Q34365776-2C98A843-F27D-43B0-AB61-818AE6DF28CD Q34436363-D9A20854-EDFB-43B6-9DCB-10691FD93E9A Q34596902-BECCC4DF-10D7-438D-8B7F-5160056A9F3A Q34843051-5CC203DF-9C9B-44FF-AF82-CE1058A16719 Q34956273-3C228EEE-BE60-4B9C-8427-1F96BCF0BF98 Q35058278-AC927F33-ADCD-4CD9-A7ED-F60F429AC5C9 Q35154638-87F047EB-3F11-4EF8-B377-9E0842113488 Q35281886-F56DAB18-CCD9-44CB-BCF5-DDF7033269D4 Q35434007-52E77EF7-AE77-4618-8068-5C2830AC1C6B Q35889130-5DCA25A1-BA4C-401C-B308-E438634B130C Q36066314-953DD173-BC5E-4615-9C17-729301C82485 Q36204370-FBF9B1AE-A355-4B39-B109-C2C1D68FC83F Q36261565-FA7BAF5D-CDA8-4DE4-9EDE-A687D0A99B36 Q36413454-D9347C9E-B15B-409A-8DDD-847BCD4D1710 Q36586981-8DBF28AA-1B93-4129-95CE-7F0A2C268E54 Q36705250-2AA22242-C894-42D4-B590-CDBB85BD5925 Q36709532-79F729DB-DFEC-4F79-B4E1-C51203E35037 Q36916874-A326BA80-3193-4BDE-A0B3-67AF53BDC057 Q37001622-39D86840-7D8A-4588-9CDB-8B2E6DB922E6 Q37079652-58D260DA-596B-4098-A4A5-895FE4D8629F Q37140728-D16E0D89-27B3-43C8-91EE-AF1C501ED4CA Q37184393-7FDF998F-5BA5-4D94-A50B-49594262FF81 Q37213050-83302F13-5B2B-4B0F-9708-E2512FAF59DE Q37229429-D9A23D9E-6E34-4ECA-BD67-003EFD597EFF Q37346570-6A4A072B-DCE1-4BBB-AEF7-83E2B34AD3E6 Q37367848-FB961595-B615-4CB0-86CB-D403829417C0 Q37479790-4EABE6EF-F355-4E85-A8D2-3218938F4FD9

P2860

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models.

http://www.wikidata.org/entity/Q40577628

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Inhibition of NFkappaB increas ...... in vivo ovarian cancer models.

@en

type

label

Inhibition of NFkappaB increas ...... in vivo ovarian cancer models.

@en

prefLabel

Inhibition of NFkappaB increas ...... in vivo ovarian cancer models.

@en

P1433

Q40577628-9685D519-3CD4-46AB-B1D5-7CE1FF77F20C

P1476

Q40577628-7F2EEE95-F405-4881-8D61-81C383BAA6B1

P2093

Q40577628-18874F0C-D567-43AF-860D-38F17D38E81E

Q40577628-23FE7C46-2C5E-4D1C-833D-BAB6BF3CE94D

Q40577628-32961485-3DA5-408F-937A-91C5B5A80949

Q40577628-603E12B2-0D5E-4863-A887-8F35726C8060

Q40577628-69068719-073F-47FD-AD55-826CA76D0B7D

Q40577628-78406B37-27EA-441E-9252-495871F852A0

Q40577628-9E129F8B-F463-4061-B798-1D12CBA202F4

Q40577628-9F0AD851-78FA-42AD-87FD-3965C5420070

Q40577628-A3F75324-F700-4E3E-AECA-F33CB4566A76

Q40577628-D7596D8D-AF3E-49AB-85AC-1FCFF3670628

P2860

Q40577628-03DA2FD2-5502-4D6C-A821-A723C993BF74

Q40577628-055C35EA-502B-4F9A-BD9E-C333C80EF259

Q40577628-0B2428B1-2221-4CFF-8929-CACA3F8FB9E7

Q40577628-0B27AFEB-5926-404B-8052-D557C6152118

Q40577628-0E8816A5-F78C-4966-A2DA-866A2F4B42B1

Q40577628-241EC235-9FC7-4241-8C4F-21902BF547BD

Q40577628-25EB9641-1FF7-4061-BCFC-973659A9F6FC

Q40577628-2D441DD0-4839-497D-A3DF-C0FB61EFA79A

Q40577628-31591F75-2674-44D0-A36E-2928722FDDC9

Q40577628-3F7A1CC9-F79B-4311-9A5E-CC2E78B43B08

P304

Q40577628-9BEED513-3470-41B0-8C6C-36C1B1621F6A

P31

Q40577628-EF6F0E16-1271-48D0-8F63-A859867B7AEF

P356

Q40577628-75BD90CB-65D0-4F11-9178-22A7E9569D66

P407

Q40577628-CBB98C84-F92F-458B-B1E1-1F22369D85E3

P433

Q40577628-17572E32-8CB1-4531-8CF7-4BFA85CF2AF6

P478

Q40577628-16267DAE-1881-42E4-8110-A492098A6026

P577

Q40577628-99639283-5492-456C-8EEA-EC8B29C558DB

P698

Q40577628-26996EA7-3432-48AC-91F7-0699C88AB0B1

P921

Q40577628-B60DE49A-298A-4CE4-97A8-3A343D13AF46

P356

P1433

Journal of Biological Chemistry

P1476

Inhibition of NFkappaB increas ...... in vivo ovarian cancer models.

@en

P2093

Akiko Kimura

http://www.w3.org/2001/XMLSchema#string

Hirohisa Kurachi

http://www.w3.org/2001/XMLSchema#string

Jun Kawagoe

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Takahashi

http://www.w3.org/2001/XMLSchema#string

Keiichi Tasaka

http://www.w3.org/2001/XMLSchema#string

Maki Saito

http://www.w3.org/2001/XMLSchema#string

Masahide Ohmichi

http://www.w3.org/2001/XMLSchema#string

Masahiro Sakata

http://www.w3.org/2001/XMLSchema#string

Namiko Yada-Hashimoto

http://www.w3.org/2001/XMLSchema#string

Seiji Mabuchi

http://www.w3.org/2001/XMLSchema#string

P2860

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways

IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

Crystal structure of p50/p65 heterodimer of transcription factor NF-kappaB bound to DNA

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

P304

23477-23485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M313709200

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

279

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15026414

http://www.w3.org/2001/XMLSchema#string

P921